Literature DB >> 18230055

The use of dexrazoxane for the prevention of anthracycline extravasation injury.

Brian B Hasinoff1.   

Abstract

BACKGROUND: The use of the anthracycline anticancer drugs doxorubicin, daunorubicin, epirubicin and idarubicin sometimes results in accidental extravasation injury and can be a serious complication of their use.
OBJECTIVE: The object of this review was to evaluate the preclinical and clinical literature on the use of dexrazoxane in preventing anthracycline-induced extravasation injury.
METHODS: A review of the literature was carried out using PubMed. RESULTS/
CONCLUSIONS: Dexrazoxane, which is clinically used to reduce doxorubicin-induced cardiotoxicity, has been shown in two clinical studies and in several case reports to be highly efficacious in preventing anthracycline-induced extravasation injury. Dexrazoxane is a prodrug analog of the metal chelator EDTA that likely acts by removing iron from the iron-anthracycline complex, thus preventing formation of damaging reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230055     DOI: 10.1517/13543784.17.2.217

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

Review 1.  Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

Authors:  James H Doroshow
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

Review 2.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 3.  Treatment of anthracycline extravasations using dexrazoxane.

Authors:  D Conde-Estévez; J Mateu-de Antonio
Journal:  Clin Transl Oncol       Date:  2013-08-15       Impact factor: 3.405

4.  Inadvertent intrathecal administration of daunomycin resulting in fatality: Case report and therapeutic considerations.

Authors:  Sauson Soldozy; Anant Patel; Kurt Yaeger; Daniel Felbaum; Steven M Spitz; Hasan R Syed; M Nathan Nair
Journal:  eNeurologicalSci       Date:  2020-11-28

5.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

6.  Tetrandrine Attenuated Doxorubicin-Induced Acute Cardiac Injury in Mice.

Authors:  Gang Li; Wen-Rui Li; Ya-Ge Jin; Qi-Qiang Jie; Cheng-Yu Wang; Lin Wu
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.